Romark Laboratories Completes Enrollment In U.S. Phase II Study Of Nitazoxanide For Chronic...
medicalnewstoday.com     May 22, 2008            

Romark Laboratories, L.C., a privately-owned biopharmaceutical company, announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in U.S. patients with chronic hepatitis C genotype 1 who... [read full story]                

Add a comment to the article
Type the code shown

View all news articles about:

- Related Topics

View other selected articles:

Generic Heartburn at Wyeth (at Motley Fool)

yahoo.com     15 hrs ago          

By Brian Orelli July 25, 2008 Comments (0) Wyeth (NYSE: WYE) has a serious case of generic-induced heartburn that's not likely to go away any time soon. Revenue from its heartburn drug Protonix dropped 59% year over year after...                

comments

                   

AG sues Mo. funeral home over mishandled bodies

charlotte.com     11 hrs ago   7 related          

The attorney general's office on Friday accused a mid-Missouri funeral home of improperly handling bodies, including storing one body in an electrical room for 10 months without being embalmed or refrigerated.The woman,...                

comments

Hepatitis cases linked to Vegas clinic

upi.com     13 hrs ago   11 related          

LAS VEGAS, July 25 (UPI) -- Nevada health officials say they have traced seven cases of hepatitis C to two patients who underwent procedures at a Las Vegas clinic last year. The Southern Nevada Health District said Thursday...                

comments

                   

Researchers disprove long-standing belief about HIV treatment

brightsurf.com     18 hrs ago   70 related          

Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated...                

comments